An interventional study of TBS in Late Life Depression (LLD), Depression - Major Depressive Disorder and Depressive Disorder, Treatment-Resistant, sponsored by Centre for Addiction and Mental Health. Recruiting at 2 sites in Canada. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder, Treatment-Resistant · Centre for Addiction and Mental Health.
Among the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 8 with no phase, and was the 14th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 40 across the 15 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
3 of the studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT06518720Centre for Addiction and Mental HealthTreatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) | 2027-03 |
| NCT06512220Centre for Addiction and Mental HealthImaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Depressive Disorder, Treatment-Resistant by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to compare the treatment efficacy (improvement in depressive symptoms) of accelerated TBS protocol (where participants receive multiple TBS treatments daily) to conventional TBS protocol (where participants receive a single TBS treatment daily) in late life depression. In addition, the study also aims to determine if specific patterns of stimulation are more or less effective. To do this, all participants will receive active treatments, but some of the participants in this study will receive accelerated TBS and some will receive once daily TBS.
The purpose of this trial is to compare the treatment efficacy (change in MADRS scores) of accelerated TBS to conventional TBS in participants with moderate to severe LLD at 4-weeks following accelerated TBS or following 30 once daily treatments of conventional TBS. Accelerated TBS group will receive 5 treatment sessions per day at approximately 1 hour intervals for 4 consecutive days on week 1 and 2 non-consecutive days on week 2. Conventional TBS group will receive 30 once daily treatment (approximately 6 weeks). Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple treatments a day (5 treatments/day) for 4 consecutive days in the first week and 2 non-consecutive days in the second week.
Device: TBS
Treatment once a day for 30 days (e.g., 5 days a week for 6 weeks)
Device: TBS
Repetitive transcranial magnetic stimulation (rTMS) is a form of non-invasive neurostimulation that uses focused magnetic field pulses to directly stimulate cortical neurons. Theta burst stimulation (TBS) is a briefer form of patterned rTMS that has been shown to be effective against major depressive disorder. Each treatment will consist of either 1) cTBS of right DLPFC followed by iTBS of left DLPFC; or 2) iTBS of left DLPFC.
Depression severity
Montgomery Asberg Depression Rating Scale (MADRS) Change
Time frame: 6 weeks
Depression severity
17 item Hamilton Depression Rating Scale (HDRS-17) Change
Time frame: up to 10 weeks
Depression severity
The Beck Depression Inventory (BDI-II) Change
Time frame: up to 10 weeks
Anxiety severity
General Anxiety Disorder-7 (GAD-7) Change
Time frame: up to 10 weeks
Suicidal ideation
The Beck Scale for Suicide Ideation (BSS) Change
Time frame: up to 10 weeks
Global cognition
Montreal Cognitive Assessment (MoCA) Change
Time frame: up to 10 weeks
Executive function
Delis-Kaplan Executive Function System (D-KEFS) Change
Time frame: up to 10 weeks
Executive function
NIH Toolbox Flanker Inhibitory Control and Attention Test
Time frame: up to 10 weeks
Memory
California Verbal Learning Test- third edition (CVLT-3) Change
Time frame: up to 10 weeks
Disability and Functional Impairment
Sheehan Disability Scale (SDS) Change
Time frame: up to 10 weeks
Quality of Life Measure
Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q) change
Time frame: up to 10 weeks
Quality of Life Measure
World Health Organization Quality of Life Short Version (WHOQOL-BREF) Change
Time frame: up to 10 weeks
Participant Expectancy of Improvement and Preference
Modified Stanford Expectations of Treatment Scale (SETS)
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Nov 2029, 56 months after the start.
Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 56 months is above that.
Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →
Centre for Addiction and Mental Health →